Article
Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors
22 Feb 2023
Abstract excerpt
Background: T cells that are genetically modified with chimeric antigen receptor (CAR) hold promise for immunotherapy of cancer. Currently, there are intense efforts to improve the safety and efficacy of CAR T cell therapies against liquid and solid tumors. Earlier we designed a novel CAR backbone (FiCAR) where the spacer is derived from immunoglobulin (Ig) -like domains of the signal-regulatory protein alpha...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
